HSV-2 Vaccine Formulations Using Segmented Polypeptides and Adjuvants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HSV-2 vaccines have shown limited efficacy and new methodologies are needed to protect against herpes diseases, as existing vaccines have been disappointing in clinical trials and have not provided long-lasting protection or effectively prevented recurrence of outbreaks.
Innovation Solution
Development of vaccine formulations comprising specific polypeptides, such as those from SEQ ID NOS: 1-38, 135, 136, 138, and 139, or their immunogenic fragments, combined with adjuvants like Quillaja saponins, to elicit an immune response and reduce HSV-2 symptoms, recurrence, and viral shedding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional HSV-2 vaccines (whole virus, protein subunit, or gene-based subunit) are used, then the vaccines are immunogenic and well tolerated, but they show limited or no efficacy in preventing HSV-2 seroconversion or blocking viral infection
Solution Approach 1:
The patent segments the HSV-2 virus into specific functional components (glycoproteins gD2, gB2, gL2, and viral proteins ICP4, UL1, UL26) and presents them as separate immunogenic units. This segmentation allows the immune system to target specific viral proteins responsible for different functions (entry, fusion, transcription), thereby improving efficacy by focusing the immune response on critical viral mechanisms rather than using whole virus or generic subunit approaches.
Solution Approach 2:
The patent creates a composite vaccine formulation combining multiple specific polypeptides (gD2, gB2, gL2, ICP4, UL1, UL26) with adjuvants (alum, MF59, or QS-21). This composite approach synergistically combines the immunogenicity of specific viral proteins with the immune-activating properties of adjuvants, resulting in enhanced protective efficacy against HSV-2 that exceeds the sum of individual components.
2Duration of action of moving object
If antiviral therapy is used to treat HSV-2 symptoms, then the duration of symptoms is limited and healing is sped up, but the virus is not cured and outbreaks recur
Solution Approach 1:
The patent applies preliminary action by administering the vaccine formulation before HSV-2 infection occurs, inducing protective immunity in advance. This preventive approach differs from antiviral therapy that acts after infection and symptom onset. The vaccine prepares the immune system beforehand with specific antibodies and T-cell responses against critical viral proteins, enabling rapid containment and elimination of the virus before it can establish latency or cause recurrent outbreaks.
3Object-affected harmful factors
If killed virus vaccines were used in the 1970s, then the vaccines are safe and immunogenic, but none were efficacious against HSV-2
Solution Approach 1:
The patent extracts and isolates specific functional proteins (gD2, gB2, gL2, ICP4, UL1, UL26) from the HSV-2 virus, separating the immunogenic components from the viral genome and non-essential proteins. This extraction approach maintains safety by using purified protein subunits rather than whole virus, while improving efficacy by focusing the immune response on specific proteins essential for viral entry, fusion, and replication, thereby eliminating the inefficacy problem of earlier killed virus vaccines.
4Quantity of substance
If attenuated HSV was used, then the vaccine is immunogenic, but it showed poor immunogenicity and limited protection
Solution Approach 1:
The patent changes the parameter of immunogen composition by using a defined combination of specific viral proteins (gD2, gB2, gL2, ICP4, UL1, UL26) rather than relying on attenuated virus. This parameter change optimizes the immunogenicity profile by selecting proteins with high immunogenic potential and critical viral functions, while the addition of adjuvants further enhances the immune response. This approach achieves both strong immunogenicity and reliable protective effect, overcoming the limitations of attenuated virus vaccines.
Data Source
AI summary
Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. Highly effective vaccines and immunogenic compositions against HSV-2, which can be used therapeutically or prophylactically, are described.